论文部分内容阅读
FDA的新药审查职责将要统一合并到美国药品评估和研究中心。目前FDA是在美国药品评估和研究中心(CDER)和生物制剂评估及研究中心(CBER)两个机构的指导下工作的。
FDA’s drug review responsibilities will be consolidated into the U.S. Center for Drug Evaluation and Research. The FDA is currently under the direction of the two agencies of the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).